Skip to search formSkip to main contentSkip to account menu

L 778,123

Known as: L 778123, L778,123, L-778,123 
A benzonitrile derivative capable of inhibiting some prenyltransferases. L-778,123 is a dual inhibitor of farnesyl:protein and geranylgeranyl:protein… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Imidazoles
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
QT Prolongation and Oncology Drug Development.
2013
2013
Comparison of Cytotoxic Activity of L778123 as a Farnesyltranferase Inhibitor and Doxorubicin against A549 and HT-29 Cell Lines.
PURPOSE Farnesyltransferase (FTase) is a zinc-dependent enzyme that adds a farnesyl group to the Ras proteins. L778, 123 is a… 
Highly Cited
2004
Highly Cited
2004
A Phase I Trial of the Dual Farnesyltransferase and Geranylgeranyltransferase Inhibitor L-778,123 and Radiotherapy for Locally Advanced Pancreatic Cancer
Purpose: Preclinical and clinical studies have demonstrated that inhibition of prenylation can radiosensitize cell lines with… 
2004
2004
Crystallographic analysis reveals that anticancer clinical candidate L-778,123 inhibits protein farnesyltransferase and geranylgeranyltransferase-I by different binding modes.
Many signal transduction proteins that control growth, differentiation, and transformation, including Ras GTPase family members… 
Review
2004
Review
2004
Farnesyl Transferase Inhibitors for Patients with Lung Cancer
The ras family of genes have been identified as potential targets for therapeutic intervention because of somatic mutations in… 
Highly Cited
2002
Highly Cited
2002
Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I.
Farnesyl:protein transferase (FPTase) inhibitors were developed as anti-Ras drugs, but they fail to inhibit Ki-Ras activity… 
Highly Cited
2002
Highly Cited
2002
A Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer.
PURPOSE Preclinical data have demonstrated that farnesyltransferaseinhibitors (FTIs) are radiation sensitizers in selected cell… 
Highly Cited
2001
Highly Cited
2001
A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies.
This Phase I study was performed to assess the feasibility of administering L-778,123, a peptidomimetic farnesyl protein… 
2001
2001
High-performance liquid chromatography/mass spectrometry characterization of Ki4B-Ras in PSN-1 cells treated with the prenyltransferase inhibitor L-778,123.
Cellular transformation by Ras oncoproteins requires the posttranslation modification of farnesylation in a reaction catalyzed by… 
Highly Cited
2000
Highly Cited
2000
Comparison of potential markers of farnesyltransferase inhibition.
Farnesyltransferase inhibitors (FTIs) were developed to target abnormal signaling pathways that are commonly activated in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)